IKZF1 and acute lymphoblastic leukemia: This finding is extremely important because it suggests that while by pathological and immunophenotypical methods can easily group this patient into CML or B-ALL at any moment, there are molecular differences in the expression of Ikaros that suggest more subtle differences in this case.